By continuing to browse our site you agree to our use of cookies, revised Privacy Policy and Terms of Use. You can change your cookie settings through your browser.
China is moving beyond being just a commercial market to becoming an innovation engine, said Amit Kakar, head of Novo Holdings Asia. As global biopharma companies ramp up local investments to bring Chinese innovative drugs to the world, they are actively capitalizing on the "China Opportunity 2.0".
China is moving beyond being just a commercial market to becoming an innovation engine, said Amit Kakar, head of Novo Holdings Asia. As global biopharma companies ramp up local investments to bring Chinese innovative drugs to the world, they are actively capitalizing on the "China Opportunity 2.0".